Fifty-Six New Medical Residents to Practice in the Valley

Translate to Spanish or other 102 languages!

Mega Doctor News

- Advertisement -

Rio Grande Valley, Texas –– The UTRGV School of Medicine (SOM) welcomed its 56 new medical residents during orientation June 22- 23 at the Edinburg Medical Education Building. The new residents began their post-graduate training July 1 in six specialties throughout the Valley.

This year, the SOM has added three new residency programs, one for Family Medicine at Knapp Medical Center, as well as one for Psychiatry, and one for Preventive Medicine. With the latest cohorts, the School of Medicine now has 140 medical residents in nine programs working at four hospitals and other institutions throughout the Valley.

Specifically, the UTRGV School of Medicine gained:

  • Six residents each for its Family Medicine residency programs with McAllen Medical Center and Doctors Hospital at Renaissance (DHR);
  • 10 residents for its Internal Medicine residency at Valley Baptist Medical Center;
  • 12 residents for its Internal Medicine residency program with DHR;
  • Four each for its Obstetrics and Gynecology, and General Surgery residency programs at Doctors Hospital at Renaissance;
  • Six residents for the Family Medicine program at Knapp Medical Center;
  • Six residents for the Psychiatry medical residency program; and
  • Two residents for the Preventive Medicine residency program. MDN
- Advertisement -
- Advertisement -

- Advertisement -

More Articles

STHS McAllen Launches Naming Contest for Advanced Surgical Robot

Using advanced robotic technology to assist surgeons in performing complex procedures with enhanced precision, dexterity and control, robotic surgery represents one of the most significant advancements in modern medicine.

DHR Health Raises Over $520K at 20th “Fishing for Hope” Event

DHR Health made a big splash at the 20th Annual “Fishing for Hope” Tournament, held on August 22 at Jim’s Pier in South Padre Island, raising an impressive grand total of $524,130.

FDA Approves First in Class Targeted Therapy for Metastatic Pancreatic Cancer

The U.S. Food and Drug Administration approved Rasonque (daraxonrasib), a RAS inhibitor for the most common form of pancreatic cancer—delivering a new treatment option to patients with advanced pancreatic cancer months ahead of schedule. 

STHS Behavioral Marks Suicide Prevention Month with Community Chalk Event

Every 11 minutes, someone in the United States dies by suicide, according to the Centers for Disease Control and Prevention (CDC), making it one of the nation's leading causes of death.
- Advertisement -